Skip to main content

Table 5 Effects of concomitant medications on the risk of HCC in different subgroups of patients with HBV (a) and HCV (b)

From: Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study

  1. CI confidence interval ACEI/ARB angiotensin converting enzyme inhibitor or angiotensin receptor blocker, DM diabetes mellitus HBV hepatitis B virus, HCV hepatitis C virus
  2. Model adjusted for age, sex, low economic income, other comorbidities (chronic obstructive pulmonary disease, transplant, and other malignancy), and medications listed in this table
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us